GlaxoSmithKline signed a $300 million research and development deal with mail gene profiling company 23andMe, gaining access to four million customers DNA information.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
